Sara K Silbert
Overview
Explore the profile of Sara K Silbert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rankin A, Duncan B, Allen C, Silbert S, Shah N
Cancer Metastasis Rev
. 2024 Dec;
44(1):17.
PMID: 39674824
The field of chimeric antigen receptor (CAR) T-cell therapy has grown from a fully experimental concept to now boasting a multitude of treatments including six FDA-approved products targeting various hematologic...
2.
Nair M, Silbert S, Rejeski K, Wilson K, Lamble A, Lamble A, et al.
Blood
. 2024 Nov;
145(11):1136-1148.
PMID: 39561284
Immune effector cell-associated hematotoxicity (ICAHT) is a major B-cell targeted chimeric antigen receptor (CAR) T-cell related toxicity. Although ICAHT incidence and severity is documented in large B-cell lymphoma (LBCL), mantle...
3.
Silbert S, Scanlon S, Wang H, Yuan C, Doverte A, Wellek J, et al.
J Immunother Cancer
. 2024 Oct;
12(10).
PMID: 39461880
Lineage switch (LS) refers to the immunophenotypic transformation of one leukemia lineage to another (ie, lymphoid to myeloid) with retention of baseline genetics. This phenomenon was originally observed in infants...
4.
Steineck A, Silbert S, Palm K, Nepper J, Vaughn D, Shipman K, et al.
Pediatr Blood Cancer
. 2024 Jun;
71(9):e31092.
PMID: 38867358
Background: Chimeric antigen receptor (CAR) T-cell therapy provides promising outcomes in relapsed/refractory B acute lymphoblastic leukemia (ALL), yet still carries high toxicity rates and relatively poor long-term survival. Efficacy has...
5.
Silbert S, Madan S, Holland E, Steinberg S, Little L, Foley T, et al.
Blood Adv
. 2023 Jul;
7(18):5566-5578.
PMID: 37486616
The tremendous success of chimeric antigen receptor (CAR) T cells in children and young adults (CAYAs) with relapsed/refractory B-cell acute lymphoblastic leukemia is tempered by toxicities such as cytokine release...
6.
Amini L, Silbert S, Maude S, Nastoupil L, Ramos C, Brentjens R, et al.
Nat Rev Clin Oncol
. 2022 Mar;
19(5):342-355.
PMID: 35318469
Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for patients with certain haematological cancers, with multiple CAR T cell products currently approved by the FDA...